tailieunhanh - Báo cáo y học: " Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer’s disease

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer’s disease. | Furuse and Hashimoto Annals of General Psychiatry 2010 9 6 http content 9 1 6 ANNALS OF GENERAL PSYCHIATRY CASE REPORT Open Access Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer s disease Tsutomu Furuse1 Kenji Hashimoto2 Abstract Background Delirium in older adults is a common and serious acute neuropsychiatric syndrome with core features of inattention and global cognitive impairment. Although antipsychotic drugs are the medications most frequently used to treat this syndrome these drugs are associated with a variety of adverse events including sedation extrapyramidal side effects and cardiac arrhythmias. Methods We report on two cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the delirium of patients with Alzheimer s disease. Results Delirium Rating Scale DRS scores in the two patients with Alzheimer s disease decreased after fluvoxamine monotherapy. Conclusion Doctors should consider that fluvoxamine could be an alternative approach in treating delirium in patients with Alzheimer s disease because of the risk of extrapyramidal side effects by antipsychotic drugs. Background Delirium in older adults is a common and serious acute neuropsychiatric syndrome with core features of inattention and global cognitive impairment 1 . Antipsychotic drugs are the medications most frequently used to treat this syndrome although exposure to these drugs can itself pose a risk for the subsequent development of delirium. Furthermore antipsychotic drugs are associated with a variety of adverse events including sedation extrapyramidal side effects and cardiac arrhythmias. Although the pathophysiology of delirium is not fully understood current evidence suggests that drug toxicity inflammation and acute stress responses can all contribute to a disruption of neurotransmission for example acetylcholine glutamate g-aminobutyric .